VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.635
+0.002 (+0.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.633
Open0.643
Bid0.635 x 1000
Ask0.635 x 1000
Day's Range0.634 - 0.660
52 Week Range0.330 - 1.020
Volume167,704
Avg. Volume1,127,354
Market Cap67.454M
Beta0.57
PE Ratio (TTM)N/A
EPS (TTM)-0.380
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • A Look at Novo Nordisk’s Human Insulin and Obesity Business
    Market Realist2 days ago

    A Look at Novo Nordisk’s Human Insulin and Obesity Business

    In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.

  • VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
    Zacks8 days ago

    VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

    VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

  • Associated Press9 days ago

    Vivus: 2Q Earnings Snapshot

    The Campbell, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15 million in the period. In the final minutes of trading on Tuesday, the ...

  • GlobeNewswire9 days ago

    VIVUS Reports Second Quarter 2018 Financial Results

    Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., Aug. 07, 2018-- VIVUS, Inc., a specialty pharmaceutical company committed to the development and commercialization of innovative therapies ...

  • ACCESSWIRE9 days ago

    VIVUS, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / VIVUS, Inc. (NASDAQ: VVUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • GlobeNewswire10 days ago

    VIVUS Appoints Kenneth Suh as President

    CAMPBELL, Calif., Aug. 06, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Suh was President and CEO of Willow Biopharma Inc., ...

  • GlobeNewswire16 days ago

    VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018

    CAMPBELL, Calif., July 31, 2018-- VIVUS, Inc. today announced that it will report financial results and provide a business update for the second quarter of 2018 after the market close on Tuesday, August ...

  • VIVUS' PAH Candidate Data Positive in Early Stage Study
    Zackslast month

    VIVUS' PAH Candidate Data Positive in Early Stage Study

    VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

  • VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session
    Zackslast month

    VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.

  • GlobeNewswirelast month

    VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106

    -Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension-. CAMPBELL, Calif., July 10, 2018-- VIVUS, Inc., a biopharmaceutical ...

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    InvestorPlace2 months ago

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...

  • Can The Uptrend Continue for VIVUS (VVUS)?
    Zacks2 months ago

    Can The Uptrend Continue for VIVUS (VVUS)?

    Investors certainly have to be happy with VIVUS, Inc. (VVUS) and its short term performance

  • GlobeNewswire2 months ago

    VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S. and Canadian rights to PANCREAZE® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) from Janssen Pharmaceuticals, Inc. (Janssen) for $135 million. Concurrently, VIVUS completed its previously announced financing agreement with Athyrium Capital Management, L.P. (Athyrium). “The restructuring of a portion of our debt coupled with the acquisition of a cash flow generating asset, PANCREAZE, will move VIVUS towards our goal of becoming an operating profit generating specialty pharmaceutical company.  The PANCREAZE transaction fits a well-defined strategy of acquiring assets utilizing VIVUS’ improving operational and financial discipline as a base platform,” said John Amos, Chief Executive Officer at VIVUS.

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    Zacks2 months ago

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
    Zacks3 months ago

    VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

  • Vivus Stock Rose 60% Last Week
    Market Realist3 months ago

    Vivus Stock Rose 60% Last Week

    Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.

  • ACCESSWIRE3 months ago

    Biotech CEO Presents: Merck’s $500M Pain, Our Potential Gain

    Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness; Vivus soared on potential to beat weight-loss drugs with significant adverse effects Bellus ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Vivus Inc Earnings Call

  • VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
    Zacks3 months ago

    VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

    VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

  • Associated Press3 months ago

    Vivus: 1Q Earnings Snapshot

    The Campbell, California-based company said it had a loss of 10 cents per share. The biopharmaceutical company posted revenue of $11.9 million in the period. In the final minutes of trading on Tuesday, ...